Sotera Health Company (SHC) is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing services for the healthcare industry. Headquartered in Broadview Heights, Ohio, SHC is renowned for its commitment to safeguarding global health. The company ensures the safety of numerous medical devices, pharmaceuticals, and food products consumed around the world every day.
With a presence in more than 50 countries, SHC operates through three important business segments, namely, Sterigenics®, Nelson Labs®, and Nordion®. Each of these segments focuses on various aspects of health protective solutions.
Sterigenics® provides tailored sterilization services to guarantee the safety of millions of vital products. Nelson Labs® provides a myriad of rigorous microbiological and analytical testing services, ensuring that products meet the necessary quality standards. Lastly, Nordion® is a pillar in the worldwide health science community, offering critical isotopes for medical applications and sterilization.
Founded in 1946, SHC leads the charge in leveraging science and technology to protect global health, helping clients mitigate risks and uphold quality control. The company is well-equipped with facilities that can handle all types of sterilization processes right from Cobalt 60 gamma irradiation to Electron Beam irradiation and Ethylene Oxide.
Over the years, SHC has upheld its reputation as an industry pioneer, boasting unparalleled expertise, regulatory knowledge, and process efficacy. This enables the company to consistently offer superior service, including contract sterilization and lab testing, with rapid turnaround times. The success of SHC can be attributed to its strong customer-centric approach, deep expertise, and stringent safety standards.
The company is deeply committed to sustainability. To minimize the impact on the environment, SHC eagerly explores and invests in opportunities to increase energy efficiency and reduce greenhouse gas emissions in its operations. Furthermore, they are deeply mindful of social responsibilities, encouraging diversity, inclusion, and fair business practices.
SHC's operations continue to expand, with a growing number of global regulatory bodies approving the use of their sterilization technologies and services. Together with its customers and partners, Sotera Health Company plays an undeniable role in maintaining global health, making a direct impact on the lives of billions of people. In doing so, SHC continues to reaffirm its position as a trusted partner in safeguarding global health.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Sotera Health (SHC) has seen its short-term momentum cool with a 6.25% share price drop over the past month, yet it still shows positive returns over 90 days and the past year. Despite the recent dip, analysts and intrinsic value estimates suggest the stock is undervalued, with a consensus target of $22.72 against its current trading price of $18.29. Investors are advised to consider underlying numbers and potential risks like ethylene oxide regulations.
Sotera Health Company (SHC) is rated as a Buy due to its strong position in medical equipment sterilization, characterized by a vertically integrated model, high customer switching costs, and robust pricing power. The company exceeded Q2 2026 expectations and raised full-year guidance, trading at a discount to peers despite superior margins. While litigation risk from ethylene oxide lawsuits exists, improving leverage and strong free cash flow support the investment case.
Sotera Health Company (SHC) reported strong second-quarter results, with earnings of $0.26 per share, surpassing the Zacks Consensus Estimate of $0.24, and revenues of $321.38 million, beating the estimate by 3.29%. The company has consistently outperformed EPS and revenue estimates over the past four quarters. Despite outperforming expectations, SHC's stock has lagged the S&P 500 this year, holding a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.
Bank of America Corp DE significantly increased its stake in Sotera Health Company (NASDAQ:SHC) by 332.7% in the first quarter, purchasing an additional 991,620 shares. This institutional activity comes amidst other large investors also modifying their holdings and recent insider selling transactions by Sotera Health executives. The company recently reported strong Q2 earnings, beating analyst estimates, and has received "Buy" and "Overweight" ratings from several Wall Street analysts, with an average price target of $21.50.
Sotera Health (NASDAQ:SHC) Chairman Michael Petras sold 850,000 shares of the company's stock for over $15.7 million, reducing his direct ownership by 17.64%. Despite this insider selling, the stock rose 2.6% to $19.00, near its 52-week high, after beating quarterly earnings and revenue estimates. Analysts maintain a "Moderate Buy" consensus with an average price target of $21.50.
The State of Wyoming acquired 56,651 shares of Sotera Health Company (NASDAQ:SHC) in the second quarter, valued at approximately $1 million. This comes as Sotera Health exceeded its quarterly earnings expectations with $0.26 EPS and $321.38 million in revenue, while institutional investors now own 91.03% of the company. Analysts maintain a "Moderate Buy" rating with an average price target of $21.50, despite an insider selling 150,000 shares.